Sandy Srinivas
Publication Details
-
A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.
Chemotherapy. 2009; (5): 321-6
Despite high response rates with front-line platinum-based therapies, 80% of patients with metastatic urothelial cancer progress. Multiple agents and couplets have been investigated, but no standard second-line regimen exists. We conducted a phase II study to evaluate the efficacy and safety of docetaxel and oxaliplatin in metastatic urothelial cancer patients who had received prior platinum therapy.
Help
Trial Administration